1	Head-to-head performance comparison of self-collected nasal
2	versus professional-collected nasopharyngeal swab for a WHO-
3	listed SARS-CoV-2 antigen-detecting rapid diagnostic test
4	
5	Julian A.F. Klein <sup>1</sup> , Lisa J. Krüger <sup>1</sup> , Frank Tobian <sup>1</sup> , Mary Gaeddert <sup>1</sup> , Federica Lainati <sup>1</sup> ,
6	Paul Schnitzler <sup>2</sup> , Andreas K. Lindner <sup>3</sup> , Olga Nikolai <sup>3</sup> , B. Knorr <sup>4</sup> , A. Welker <sup>4</sup> ,
7	Margaretha de Vos <sup>5</sup> , Jilian A. Sacks <sup>5</sup> , Camille Escadafal <sup>5</sup> , Claudia M. Denkinger <sup>1,§</sup> for
8	the study team
9	<sup>1</sup> Division of Clinical Tropical Medicine, Centre of Infectious Diseases, Heidelberg University
10	Hospital, Germany
11	<sup>2</sup> Department of Virology, Centre of Infectious Diseases, Heidelberg University Hospital,
12	Germany
13	<sup>3</sup> Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin,
14	Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of Tropical Medicine
15	and International Health, Berlin, Germany
16	<sup>4</sup> Local Health Authority of Heidelberg and Rhein-Neckar-Region, Germany
17	<sup>5</sup> Foundation for Innovative New Diagnostics, Geneva, Switzerland
18	Correspondence: Claudia M. Denkinger, Division of Clinical Tropical Medicine, Heidelberg
19	University Hospital, Im Neuenheimer Feld 324, 69120 Heidelberg, Germany. E-mail:
20	claudia.denkinger@uni-heidelberg.de
21	Key Words: SARS-CoV-2, COVID-19, nasal sampling, antigen-detecting rapid diagnostic

22 test, self-sampling, head-to-head comparison. NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

## 23 *To the Editor:*

24 The use of antigen-detecting rapid diagnostic tests (Ag-RDTs) for SARS-CoV-2 has increased within the last months and has an important role in pandemic management. However, broader 25 use and scale up is limited due to complex sampling methods. In 2020, the World Health 26 Organization (WHO) recommended two lateral flow Ag-RDTs ((SD Biosensor, Inc. 27 Gyeonggi-do, Korea, distributed by Roche, Germany, henceforth called Standard Q; and 28 Abbott Panbio<sup>™</sup> (Rapid Diagnostics, Jena, Germany; henceforth called PanBio)), both 29 initially with nasopharyngeal (NP) sample collection [1,2]. Since then, independent head-to-30 head studies demonstrated that nasal sampling (including self-sampling) assessed against NP 31 32 sampling leads to comparable performance using the SARS-CoV-2 Ag-RDT SD STANDARD Q [3-5]. For Panbio, only one study to date assessed professional nasal mid-turbinate (NMT) 33 sampling and showed 82.1% sensitivity and 99.1% specificity in comparison to reverse 34 35 transcription polymerase chain reaction (RT-PCR). However, a head-to-head comparison with NP sampling has not been performed to date [6]. 36

We conducted a manufacturer-independent prospective study directly comparing the diagnostic accuracy of Panbio performed with a supervised, self-collected NMT swab versus a professionally collected NP swab. For the two Ag-RDT sampling techniques positive and negative percent agreements (PPA, NPA) were calculated. Sensitivity and specificity were assessed and compared against the reference standard RT-PCR.

The ethical review committee at Heidelberg University Hospital approved the study protocol (registration number S-180/2020). Enrollment and testing took place in Heidelberg (Germany) between December 15<sup>ths</sup> 2020 and January 19<sup>ths</sup> 2021 in a *SARS-CoV-2* drive-in testing centre, led by the local health authority. We included adults with symptoms suggestive for a *SARS-CoV-2* infection or a recent high-risk contact with a confirmed *SARS-CoV-2* case.

After written informed consent, each participant was instructed to self-collect a NMT swab 47 48 for the Ag-RDT under supervision using a non-flocked swab (Jiangsu Changfeng Medical Industry Co., Ltd., Jiangsu, China), provided by Abbott in the research use only Panbio kit for 49 nasal swab testing. The instructions were verbal and picture-guided following the 50 manufacturer's instructions for use. In a second step, a health worker collected a NP swab 51 52 (using IMPROSWAB®, Guangzhou Improve Medical Instruments Co., Ltd., Guangzhou, 53 China), for RT-PCR testing in one nostril. Finally, a second NP swab for Ag-RDT testing was collected from the patient using a nylon-flocked specimen (NFS-SWAB Applicator<sup>™</sup>, Noble 54 55 Bioscienes Inc., Gyeonggi-do, Korea), provided with the commercial Abbott 56 (nasopharyngeal) test kit. The PanBio was conducted on-site by trained study personnel following the manufacturer's instruction for use for each kit [7]. Two study staff read out the 57 Ag-RDT results, each of them blinded to the interpretation of the other. 58

For RT-PCR testing the Tib Molbiol® (Berlin, Germany) assay was used. Viral load (VL) values were calculated based on a calibration curve and the assay specific cycle threshold (Ct)-value [8]. Leftover samples of the NMT and NP swabs resuspended in Ag-RDT buffer were stored at -20 degrees Celsius. Samples that were identified to be false-positive in comparison to RT-PCR on one or both Ag-RDTs were retested with RT-PCR from the remnant Ag-RDT buffer.

We screened a total of 369 eligible individuals of whom 292 (79.1%) gave written consent. After exclusion of two participants (one with invalid RT-PCR result and one with lost written informed consent), 290 participants were included in the analysis (study flow detailed in Supplementary Material (B)). Our study population had an average age of 42.7 years (standard deviation (SD) 14.6), 33.8% (98/290) had comorbidities and 52.4% (152/290) were female. In total, 45.9% (133/290) were symptomatic on the day of testing with a mean duration of symptoms of 3.8 days (SD 5.4). *SARS-CoV-2* infection was detected by RT-PCR

in 15.5% (45/290) of the study population (Table 1), with eight infections being among
asymptomatic participants. One invalid Ag-RDT was registered on NP samples, which was
valid upon repeat.

75 The overall sensitivity of Panbio with NP sampling was 88.9% (40/45; 95% confidence interval (CI) 76.5% - 95.5%) and 84.4% (38/45; CI 71.2% - 92.3%) with NMT sampling. 76 Four infections were identified by NP Ag-RDT sampling, which were negative in NMT 77 78 sampling of which two had a low VL (VL <4.9 log<sub>10</sub> SARS-CoV-2 RNA copies/ml) and two were asymptomatic (Table 1). Two participants had a positive NMT result, not detected via 79 NP Ag-RDT, of which one had a low VL (VL <4.9 log<sub>10</sub> SARS-CoV-2 RNA copies/ml). 80 81 Specificity was 99.2% (243/245; CI 97.1% - 99.8%) for both, NP and NMT sampling. Considering only RT-PCR positive participants with high VL (>  $7 \log_{10} SARS-CoV-2$  RNA 82 copies/mL), the sensitivity of the Panbio test was 96.3% (CI 81.7% - 99.8%) for both NMT 83 and NP sampling. Excluding nine participants with oropharyngeal sampling instead of NP 84 (due to contraindications of NP sampling) increased sensitivity only marginally (40/44; 90.9% 85 86 (CI 78.8% – 96.4%)). Detailed results by symptoms and sub-group analyses are available in the Supplement (C&D). The positive percent agreement of the Ag-RDT was 88.1% (37/42 87 PCR positives detected; CI 75.0% - 94.8%) including one false-positive by both NMT and 88 89 NP, and one false-positive by NP only. The negative percent agreement was 98.8% (245/248; CI 96.5% - 99.6%). Inter-rater reliability for the interpretation of the Ag-RDTs was perfect 90 91 with a kappa of 1.0. Participants reported NMT sampling to be better tolerated than NP 92 sampling.

When performing RT-PCR from the remnant buffer/sample-mixture, SARS CoV-2 was identified in both NMT and NP samples from the same participant with a false-positive Ag-RDT result. This suggests the Ag-RDT result being in fact true-positive with a sampling error likely having occurred for the RT-PCR from NP sample. For two other false-positives, one

97 each on NMT and NP, no virus was identified in the buffer solution. Among three false98 negative NMT samples one buffer was positive with low VL (4.38 log<sub>10</sub> SARS-CoV-2 RNA
99 copies/ml; Supplementary Material (F), suggesting that the VL was below the limit of
100 detection of the Ag-RDT.

Our study has several strengths. Study methods were rigorous and included standardized sampling and two independent blinded readers. The study population is representative, judging from the similar sensitivity of the Panbio test with NP sampling observed in our study in comparison to two large validation studies [9,10]. All samples for routine RT-PCR were tested via the same RT-PCR assay (Table 1). The RT-PCR on the leftover buffer solution of Ag-RDT allowed us to perform further discrepant analysis.

A limitation of the study is that it was performed in a single centre. The preselection of 107 108 participants invited to come for testing was done according to national guidelines. We did not record deviations from the recommended NMT procedure, however as the sampling was done 109 110 under proactive supervision, no major deviations were observed. Readers were not blinded to 111 the sampling method while interpreting the test results, but weak positive results are rarely observed with the Panbio test, thus this limitation is unlikely to result in a difference in result 112 interpretation. In the discrepant analysis, we did not perform RT-PCR of all Ag-RDT buffer 113 114 solutions thus introducing a possible bias.

Our study suggests that supervised NMT self-sampling leads to results comparable to NP sampling for the PanBio Ag-RDT. A possible reduction in VL present in the nasal region compared to the nasopharyngeal region may be counterbalanced by the ease-of-sampling. Results of nasal sampling could potentially be further improved, if flocked swabs were used [11]. Standardized easy self-sampling methods are highly desirable, as they could increase

- throughput and require fewer medical personnel, which is often a bottle neck for scaling of
- 121 antigen testing.

122 Acknowledgements: Angelika Sandritter, Andrea Sieber, Alexander Syring, Zoe Solomon,

- 123 Emilija Mitreska, Sabrina Eisenmann, Andrea Fuhs, Kholoud Assaad, Salome Steinke.
- 124 **Declaration of interest statement**: None declared.

Funding: The study was supported by Heidelberg University Hospital internal funds, as well as a grant of the Ministry of Science, Research and the Arts of Baden-Württemberg, Germany. Foundation of Innovative New Diagnostics (FIND) reports grants from UK Department of International Development (DFID, recently replaced by FCMO), grants from World Health Organization (WHO), grants from Unitaid, to conduct the study.

## 130 **References**

- 131 1. World Health Organization. Global partnership to make available 120 million
- affordable, quality COVID-19 rapid tests for low- and middle-income countries 2020,
- 133 September 28th. Available from: <u>http://www.who.int/news-room/detail/28-09-2020-</u>
- 134 global-partnership-to-make-available-120-million-affordable-quality-covid-19-rapid-

135 <u>tests-for-low--and-middle-income-countries</u>. Date last accessed: February 24 2021

- 136 2. World Health Organization. WHO Emergency Use Assessment Coronavirus disease
- 137 (COVID-19) IVDsPUBLIC REPORT, Product: Panbio COVID-19 Ag Rapid Test
- 138 Device (NASAL) 2021 January. Available from: <u>https://extranet.who.int/pqweb/key-</u>
- 139 resources/documents/who-eul-public-report-abbott-panbio-covid-19-ag-rapid-test-
- 140 <u>device-nasal-eul</u>. Date last accessed: February 24 2021
- 141 3. Lindner AK, Nikolai O, Kausch F, et al. Head-to-head comparison of SARS-CoV-2
- 142 antigen-detecting rapid test with self-collected nasal swab versus professional-
- 143 collected nasopharyngeal swab. Eur Respir J. 2021 Feb 18.
- 4. Lindner AK, Nikolai O, Rohardt C, et al. Head-to-head comparison of SARS-CoV-2
- 145 antigen-detecting rapid test with professional-collected nasal versus nasopharyngeal
- swab. Eur Respir J. 2021 Feb 11.

al
al
al
-
e of
are
)S

168

- **TABLE 1** Ag-RDT results with a supervised self-collected nasal mid-turbinate (NMT) swab
- and professional-collected nasopharyngeal (NP) swab in RT-PCR positive patients.

	(NMT Ag-RDT (NP b) swab) lected profcollected	RT-PCR (NP swab)		
Ag-RDT (NMT swab) self-collected		Ct-value*	Viral load (log <sub>10</sub> SARS-CoV- 2 RNA copies/ml)	Symptom duration (days)
positive	positive	12.7	10.0	2
positive	positive	12.9	9.9	4
positive	positive	13.1	9.9	3
positive	positive	16.1	9.0	3
positive	positive	16.4	8.9	3
positive	positive	16.5	8.9	2
positive	positive	16.5	8.9	1
positive	positive	16.6	8.9	1
positive	positive	16.7	8.8	1
positive	positive	17.8	8.5	0
positive	positive	17.9	8.5	1
positive	positive	18.8	8.2	2
positive	positive	18.8	8.2	7
positive	negative	18.9	8.2	1
positive	positive	19.5	8.0	5
positive	positive	19.7	7.9	1
positive	positive	19.9	7.9	4
positive	positive	19.9	7.9	asymptomatic <sup>#</sup>
positive	positive	20.1	7.8	asymptomatic <sup>#</sup>
positive	positive	20.2	7.8	10
positive	positive	21.2	7.5	2
positive	positive	21.4	7.4	asymptomatic <sup>#</sup>
negative	positive	22.1	7.2	1
positive	positive	22.5	7.1	5
positive	positive	22.5	7.1	2
positive	positive	22.6	7.1	6
positive	positive	22.8	7.0	5
positive	positive	23.1	6.9	asymptomatic <sup>#</sup>
positive	positive	23.1	6.9	1
positive	positive	23.6	6.8	5
positive	positive	23.8	6.7	2
positive	positive	25.7	6.2	2

positive	positive	25.9	6.1	7
positive	positive	26.0	6.1	6
positive	positive	26.3	6.0	asymptomatic <sup>#</sup>
positive	positive	26.7	5.9	1
negative	negative <sup>1</sup>	26.7	5.9	1
positive	positive	27.7	5.6	2
negative	positive	29.7	5.0	asymptomatic <sup>#</sup>
negative	negative	30.6	4.7	asymptomatic <sup>#</sup>
positive	positive	31.2	4.5	1
positive	negative	31.2	4.5	1
negative	positive	32.7	4.1	n.a.
negative	positive	33.8	3.8	asymptomatic <sup>#</sup>
negative	negative	34.5	3.6	10
Sensitivity	Sensitivity			
84 4% (38/45.	88.9% (40/45)			

<u>CI 71.2% – 92.3%)</u> <u>CI 76.5% – 95.5%)</u> Positive Percent Agreement 88.1% (CI 75.0% – 94.8%)\*\*

- 171 \*Assay: TibMolBiol
- 172 *\*\*including one false-positive on NMT and NP and one on NP*
- 173 <sup>#</sup>on the day of testing
- <sup>174</sup> <sup>1</sup>oropharyngeal swab due to contraindications of NP Sampling
- 175 Abbreviations: Ag-RDT: antigen-detecting rapid diagnostic test; NMT: nasal mid-turbinate;
- 176 NP: nasopharyngeal; Ct: cycle threshold; RT-PCR: reverse transcription-polymerase chain
- 177 reaction; n.a.: not available. CI: confidence interval